New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Gilead Sciences, Inc.

GILD

Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.

Revenue
+6.83%
EPS
−20.2%
Free cash flow
+21.1%
Total debt
+5.17%

Quarter to September 2026, against a year earlier

168.69 2.16 +1.30%
Market cap
$207.8B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
1.95%
F-score
8/9
ROIC
−4.51%
Net debt / EBITDA
1.4×
Payout ratio
—

Gilead Sciences, Inc. (GILD) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 11 added · 7 removed · 35 modified
P2I1A: 1 removed · 29 modified
8-K Oct 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 33 added · 8 removed · 31 modified
P2I1A: 2 added · 1 removed · 28 modified
8-K Aug 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 14, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026 P1I2: 19 added · 64 removed · 28 modified
P2I1A: 1 added · 3 removed · 39 modified
8-K May 7, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 30, 2026 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
8-K Apr 28, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 4 added · 9 removed · 34 modified
1A: 11 added · 7 removed · 43 modified
7: 39 added · 41 removed · 48 modified
8-K Feb 22, 2026 1.01 Entry into a material definitive agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Feb 10, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 15, 2025 5.02 Departure or appointment of directors or officers Officer departure
10-Q Sep 30, 2025 P1I2: 40 added · 12 removed · 35 modified
P2I1A: 4 added · 5 removed · 30 modified
8-K Oct 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 6, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025 P1I2: 30 added · 19 removed · 31 modified
P2I1A: 3 added · 1 removed · 39 modified
8-K Aug 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K Apr 24, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024 1: no comparison — no earlier filing on file
1A: no comparison — no earlier filing on file
7: no comparison — no earlier filing on file
8-K Feb 11, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 25, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.